Leerink Partnrs Issues Positive Estimate for BNTC Earnings

Benitec Biopharma Inc. (NASDAQ:BNTC) – Investment analysts at Leerink Partnrs raised their Q3 2025 earnings estimates for Benitec Biopharma in a research report issued on Monday, March 31st. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will earn ($0.26) per share for the quarter, up from their prior forecast of ($0.28). The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.48) per share. Leerink Partnrs also issued estimates for Benitec Biopharma’s Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.22) EPS and FY2026 earnings at ($1.19) EPS.

Benitec Biopharma (NASDAQ:BNTC) last issued its earnings results on Friday, February 14th. The biotechnology company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.19.

A number of other analysts also recently issued reports on BNTC. Baird R W raised shares of Benitec Biopharma to a “strong-buy” rating in a report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and set a $28.00 target price on shares of Benitec Biopharma in a research note on Monday, March 24th. Finally, Robert W. Baird assumed coverage on Benitec Biopharma in a report on Friday, December 13th. They set an “outperform” rating and a $30.00 price target on the stock. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Benitec Biopharma has a consensus rating of “Buy” and an average price target of $24.43.

Benitec Biopharma Price Performance

Benitec Biopharma stock opened at $12.55 on Thursday. Benitec Biopharma has a one year low of $4.75 and a one year high of $16.90. The business’s fifty day moving average is $12.37 and its 200 day moving average is $11.22. The stock has a market capitalization of $294.31 million, a PE ratio of -8.31 and a beta of 0.76.

Insider Transactions at Benitec Biopharma

In related news, Director Suvretta Capital Management, L acquired 900,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 26th. The stock was bought at an average cost of $13.00 per share, for a total transaction of $11,700,000.00. Following the purchase, the director now owns 8,793,245 shares in the company, valued at $114,312,185. The trade was a 11.40 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 1.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Benitec Biopharma

Several large investors have recently added to or reduced their stakes in the company. Northern Trust Corp increased its stake in shares of Benitec Biopharma by 54.2% in the fourth quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company’s stock worth $482,000 after purchasing an additional 13,425 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Benitec Biopharma by 31.3% in the third quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company’s stock valued at $772,000 after acquiring an additional 20,012 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Benitec Biopharma by 138.4% in the fourth quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company’s stock worth $448,000 after acquiring an additional 20,597 shares during the period. Lion Point Capital LP boosted its stake in shares of Benitec Biopharma by 59.0% in the fourth quarter. Lion Point Capital LP now owns 62,000 shares of the biotechnology company’s stock worth $783,000 after acquiring an additional 23,000 shares during the period. Finally, 683 Capital Management LLC purchased a new stake in shares of Benitec Biopharma during the fourth quarter worth about $452,000. Hedge funds and other institutional investors own 52.19% of the company’s stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.